Author/Date | # children on HAART | Age at initiation | Duration of follow up | CD4 at initiation | Adherence | Survival | Loss to Follow-Up |
---|---|---|---|---|---|---|---|
Abrams 2005 [18] | 144 | Â | Median 19 months (Range 2 months - 12 years) | Â | Â | Â | Â |
Van Griensven 2008 [28] | 332 | Median 7.2 years (IQR 4.5-10.4) | Median 2.0 years (IQR 1.2-2.6) | Median 14% (IQR 9-18%) | 49%: >95% adherence 46%: >80% adherence | 98% survival at 12 months 8 deaths (2.6% mortality) | 12 children (3.8%) |
Eley 2004 [22] | 80 | Median 1.25 years (Range .003-12.0) | Â | Â | "Most": >85% adherence | 7 deaths (8.8% mortality) | 4 children (5%) |
Habibu 2006 [23]* | 52 | Â | Â | Â | >95% adherence | Â | 0 children |
Lusiama 2004 [24]* | 393 | Median 7.5 (years) (IQR 4.3-10.5) | Median 21.9 months (IQR 7.5-25.9) | Median 12% (IQR 7-18%) | Â | 30 deaths (8% mortality) | 44 children (9%) |
Midturi 2008 [25]* | 56 | Mean 39.6 months | Mean 14.7 months | Â | 77.8% adherence | 1.8% mortality | 1.8% |
Reddi 2007 [26] | 151 | Median 5.7 years (Range 0.3-15.4) | Median 8 months (IQR 3.5-13.5) | Median 7.4% (IQR 2.1-13.7%) | 59.6%: no missed doses 29.8%: >95% adherence | 90.9% survival at 12 months 13 deaths (8.6% mortality) | 0 children |
Tonwe-Gold 2009 [27] | 43 | Â | Median 12 months (IQR 5.0-15.0) | Â | Â | 2 deaths (4.9% mortality) | 0 children |
Van Winghem 2008 [29] | 657 | Median 5.5 years (IQR 3.2-8.7) | Median 1.36 years (IQR 0.6-2.2) | Â | Â | 95.3% survival at 12 months 7 deaths (6.7% mortality) | 67 children (10.2%) |